Activation of the ATR kinase following perturbations to DNA replication relies on a complex mechanism involving ATR recruitment to RPA-coated single-stranded DNA via its binding partner ATRIP and stimulation of ATR kinase activity by TopBP1. Here, we discovered an independent ATR activation pathway in vertebrates, mediated by the uncharacterized protein ETAA1 (Ewing's tumour-associated antigen 1). Human ETAA1 accumulates at DNA damage sites via dual RPA-binding motifs and promotes replication fork progression and integrity, ATR signalling and cell survival after genotoxic insults. Mechanistically, this requires a conserved domain in ETAA1 that potently and directly stimulates ATR kinase activity independently of TopBP1. Simultaneous loss of ETAA1 and TopBP1 gives rise to synthetic lethality characterized by massive genome instability and abrogation of ATR-dependent signalling. Our findings demonstrate that parallel TopBP1-and ETAA1-mediated pathways underlie ATR activation and that their combined action is essential for coping with replication stress.
Alterations to the content and organization of cellular genomes, inflicted by numerous genotoxic insults, may lead to pathological conditions such as cancer, premature ageing and neurodegeneration 1, 2 . To mitigate this threat, cells mount a coordinated DNA damage response (DDR) that promotes repair of DNA lesions and delays cell cycle progression until genome integrity has been restored 3, 4 . The ATM and ATR kinases are master organizers of the DDR that trigger damage-specific signalling cascades through direct phosphorylation of large numbers of effector proteins, including the checkpoint kinases Chk1 and Chk2 (refs 4-10) . The physiological importance of these kinases in protecting genome stability is illustrated by patients with Ataxia telangiectasia and Seckel syndromes, caused by mutations in ATM and ATR, respectively, which manifest with a range of severe disabilities 11, 12 . Whereas ATM is mainly activated by DNA double-strand breaks (DSBs), ATR is the major kinase responding to replication stress, a potentially deleterious condition defined by a slowdown or block to replication fork progression, caused by a broad range of perturbations including DNA damage, nucleotide shortage, and replication-transcription collisions 13, 14 . ATR is essential for ensuring the fidelity of DNA replication after such insults, suppressing new origin firing, preventing fork collapse and promoting the restart of stalled forks. Consequently, disruption of the ATR gene causes early embryonic lethality in mice 15, 16 .
Replication protein A (RPA)-coated single-stranded DNA (ssDNA) regions generated by uncoupling of replicative helicase and polymerase movements after fork stalling or by DSB end resection provide a main stimulus for activation of ATR, which is recruited to these structures via its obligate binding partner ATRIP [17] [18] [19] . In parallel, the PCNA-like Rad9-Rad1-Hus1 (9-1-1) complex is loaded onto junctions of ssDNA and double-stranded DNA (dsDNA), leading to recruitment of the multi-BRCT domain-containing protein TopBP1 via Rad9 phosphorylation, the Mre11-Rad50-Nbs1 (MRN) complex, and the RHINO protein [20] [21] [22] [23] [24] [25] . TopBP1 directly stimulates ATR kinase activity by means of an ATR-activating domain (AAD) that may induce conformational changes of the ATR kinase domain 26, 27 , and whose integrity is essential for viability in mice 28 . While TopBP1 is the only protein known to harbour an AAD in higher eukaryotes, two additional proteins in Saccharomyces cerevisiae, the Rad9 orthologue Ddc1 and the exonuclease Dna2, also contain AADs 29, 30 . These factors play partially redundant roles in promoting activation of Mec1, the ATR orthologue in budding yeast, and simultaneous knockout of all three AAD-containing proteins is required to abrogate Mec1-dependent checkpoint signalling in S phase 1) as an RPA-binding protein that harbours a potent AAD and operates in parallel with, but independent of, the canonical 9-1-1/TopBP1 axis to promote ATR signalling following replication stress. Loss of ETAA1 disrupts the integrity of the DNA replication programme, sensitizes cells to replication stress and displays synthetic lethality with TopBP1 depletion, characterized by abrogation of ATR-dependent checkpoint signalling and massive genomic instability. Thus, ATR activation in human cells relies on dual TopBP1-and ETAA1-mediated pathways whose combined action is essential for coping with replication stress.
RESULTS

Systematic profiling of DNA DSB-containing chromatin
We recently developed a mass spectrometry-based approach (CHROMASS) to systematically profile protein recruitment to chromatin containing DNA interstrand crosslinks in Xenopus egg extracts 31 . To extend these surveys, we applied CHROMASS and label-free mass spectrometry to study protein enrichment dynamics at chromatin modified with nuclease-generated DNA DSBs (Fig. 1a) . At early time points, we observed strong enrichment of virtually all known core factors in classical non-homologous end-joining (c-NHEJ), a major DSB repair pathway (Fig. 1b,c and Supplementary  Tables 1 and 2 ). At later time points, the ssDNA-binding RPA complex (rfa1-3) and known RPA interactors (including ATR-ATRIP, SMARCAL1 (smal1), rfwd3 and helb) also became enriched on the damaged chromatin (Fig. 1b,d and Supplementary Tables 1 and 2) , indicative of progressive DSB end resection. In addition to many established DSB repair factors, these screens revealed potential new components of DNA damage signalling and repair pathways, one of which we characterize below. These data demonstrate that CHROMASS is a powerful method for comprehensive profiling of the dynamic protein landscape at DSB-modified chromatin.
ETAA1 is a potential DDR factor linked to RPA
Among factors showing recruitment to DSB-containing chromatin in the Xenopus system, we identified an uncharacterized protein, etaa1, which became markedly enriched on damaged chromatin together with RPA and RPA-binding factors (Fig. 1b-d) . High sequence coverage allowed quantification of etaa1 across the data set, revealing strikingly similar intensity profiles of etaa1, RPA subunits and known RPA interactors ( Supplementary Fig. 1a-c) . Moreover, etaa1 showed strong enrichment on undamaged chromatin following inhibition of DNA polymerases by aphidicolin ( Supplementary Fig. 1d and Supplementary Table 3 ), which causes extensive RPA-ssDNA generation through uncoupling of replicative polymerases and helicases 17 . This suggests that the function of etaa1 is tightly linked to RPA.
To characterize the cellular function of etaa1, we focused on the human orthologue, ETAA1, an uncharacterized 926-amino-acid protein 32 . When expressed stably in human cells, GFP-tagged ETAA1 underwent redistribution to laser-induced DSBs demarcated by γH2AX positivity (Fig. 1e,f) . Consistent with the strong clustering of etaa1 with RPA and RPA interactors in CHROMASS experiments ( Supplementary Fig. 1b ), ETAA1 was recruited to DNA damage sites only in cells displaying RPA1 accumulation, and the ETAA1 and RPA1 signals co-localized in a microfoci-like pattern contained within the more expanded γH2AX regions at laser stripes (Fig. 1e,f) 
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. ETAA1 also formed nuclear foci co-localizing with RPA after short-term exposure to camptothecin (CPT), which induces replication-dependent DSBs, and hydroxyurea (HU), which causes helicase-polymerase uncoupling but little DSB formation (Fig. 1g) . We conclude that ETAA1 is recruited to RPA-coated ssDNA regions generated following genotoxic insults in vertebrate cells.
ETAA1 accumulates at DNA damage sites through direct binding to RPA
The observations above suggested that ETAA1 might be recruited to DNA damage sites through direct binding to RPA. Consistently, inhibition of RPA accumulation at DSB sites by knockdown of CtIP, a key factor in DSB end resection 34 , or RPA1, suppressed ETAA1 recruitment to damaged DNA, while depletion of core homologous recombination (HR) factors such as BRCA2 or RAD51 had no effect ( Fig. 2a and Supplementary Fig. 2a ). Moreover, ETAA1 and RPA subunits interacted in reciprocal co-immunoprecipitation assays (Fig. 2b,c) . Expression of a series of ETAA1 fragments showed that its carboxy-terminal portion contained the RPA-binding determinant ( Supplementary Fig. 2b ). Inspection of the primary sequence of this region revealed an evolutionarily conserved motif in the extreme C terminus of ETAA1 showing striking homology with the RPA2-binding motifs in SMARCAL1, XPA and TIPIN (Fig. 2d ) [35] [36] [37] . Indeed, removal of the C-terminal region in RPA2 recognized by these motifs impaired its interaction with ETAA1 (Fig. 2c) . Deletion of the ETAA1 C terminus containing the putative RPA2-binding motif ( RBM2) or point mutations of key conserved residues predicted to impair its functional integrity 35, 36 suppressed the RPA-binding ability of ETAA1 and its recruitment to DSBs (Fig. 2b ,e,f and Supplementary Fig. 2c-f) . However, the ETAA1 RBM2 mutant displayed weak accumulation at DNA damage sites in a small proportion of cells (Fig. 2e,f) , suggesting that additional sequence determinants in ETAA1 also contribute to its DNA damage recruitment. To this end, we noticed a sequence in the central portion of ETAA1 with similarity to known RPA1-binding motifs in ATRIP, NBS1 and RAD9 (Fig. 2d ) 38 . While deletion of this sequence alone ( RBM1) had no impact on the ability of ETAA1 to interact with RPA and DNA damage sites, simultaneous ablation of both RPA-binding motifs ( RBM1+2) fully suppressed ETAA1 recruitment to damaged DNA but did not impair RPA accumulation (Fig. 2b ,e,f and Supplementary Fig. 2e,f) . These data suggest that ETAA1 contains two RPA-binding determinants that jointly underlie its stable retention at DNA damage sites.
ETAA1 contains an ATR-activating domain
We next asked how ETAA1 functions in the DDR. Strikingly, overexpression of full-length ETAA1 led to strong, pan-nuclear γH2AX positivity independently of its binding to RPA (Fig. 3a,b) . Instead, deleting amino-terminal portions of ETAA1 suppressed its ability to promote γH2AX formation, and overexpression of these regions alone was sufficient to trigger H2AX phosphorylation, similar to the TopBP1-AAD (Fig. 3a,b and Supplementary Fig. 3a,b) A R T I C L E S Figure 1 Systematic profiling of DSB-containing chromatin reveals ETAA1 as a potential DDR factor. (a) CHROMASS workflow to analyse protein recruitment to DSB-containing chromatin. Sperm chromatin was incubated in Xenopus egg extract and DSBs were induced by addition of PflMI enzyme. After various times, chromatin was isolated by centrifugation through a sucrose cushion and analysed by label-free mass spectrometry (MS). m/z, mass-to-charge ratio. (b) Heatmap showing the mean of the z-scored protein intensities of selected factors for DSB-containing chromatin normalized to the undamaged control (n = 3 independent experiments). See Supplementary Table 2 for recruitment profiles for all quantified proteins. (c) Protein recruitment to DSB-containing chromatin at 15 min compared with an undamaged control. The volcano plot shows the mean difference of the protein intensity (log 2 ) plotted against the P value resulting from a onesided modified t-test (see Methods, n = 3 independent experiments for both groups). The dashed line indicates the significance cutoff. (d) Protein recruitment to DSB-containing chromatin at 45 min, plotted as in c. (e) U2OS cells stably expressing GFP-ETAA1 were subjected to laser microirradiation, fixed 1 h later and co-immunostained with RPA1 and γH2AX antibodies.
(f) Quantification of data in e (mean ± s.d.; n = 3 independent experiments; 80 cells analysed per experiment). Neg., negative; Pos., positive. (g) U2OS cells stably expressing GFP-ETAA1 were treated with CPT (1 h) or HU (3 h), fixed and co-immunostained with RPA1 and γH2AX antibodies. All scale bars, 10 µm. Data are representative of three (e) and two (g) independent experiments with similar results.
impact on ETAA1 recruitment to DNA damage sites but abolished γH2AX formation following ETAA1 overexpression (Fig. 3a,b) , further suggesting that this activity is uncoupled from its RPAbinding ability. To characterize the ability of ETAA1-AAD to induce γH2AX formation, we fused this sequence to GFP and an oestrogen receptor variant (ERT2), allowing for swift nuclear translocation of otherwise cytoplasmic GFP-ETAA1-AAD-ERT2 following treatment with 4-hydroxy-tamoxifen (4-OHT) (Fig. 3c,d) . Exposure of cells 
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Percentage of GFP-ETAA1/RPA co-localizing stripes stably expressing GFP-ETAA1-AAD-ERT2 to 4-OHT triggered rapid pan-nuclear γH2AX positivity irrespective of cell cycle position (Fig. 3d-f and Supplementary Fig. 3c ). This effect resembled that of an analogous system for 4-OHT-controlled nuclear expression of TopBP1-AAD 39 ; however, ETAA1-AAD promoted γH2AX formation at lower expression levels than TopBP1-AAD ( Supplementary Fig. 3d ). Several lines of evidence suggested that similar to TopBP1-AAD 39 , the γH2AX positivity caused by ETAA1-AAD overexpression was not a consequence of DNA breakage. First, the ETAA1-AAD-induced γH2AX signal was pan-nuclear rather than focal (Fig. 3a,d ,e) and it was not accompanied by RPA foci formation and chromatin loading ( Supplementary Fig. 3e ). Second, treatment with kinase inhibitors or short interfering RNAs (siRNAs) showed that the γH2AX-promoting ability of ETAA1-AAD was independent of the DSB-responsive kinases ATM and DNA-PK, whereas the kinase activity of ATR was essential ( Fig. 3f ; see also Supplementary Fig. 6a-c) .
As ATR is capable of phosphorylating H2AX like ATM and DNA-PK 40 , these data suggested that ETAA1-AAD directly stimulates ATR kinase activity similar to TopBP1-AAD. Indeed, both fulllength ETAA1 and ETAA1-AAD alone interacted with ATR in coimmunoprecipitation assays ( Fig. 3g and Supplementary Fig. 3f ). When incubated with purified ATR-ATRIP complex, recombinant ETAA1-AAD markedly stimulated ATR kinase activity towards MCM2 in vitro (Fig. 3h) , strongly suggesting that this domain is a bona fide AAD. The TopBP1-AAD contains a conserved tryptophan residue (Trp1145 in human TopBP1) that is essential for its ability to stimulate ATR kinase activity 26 . Strikingly, the sequence spanning this residue displayed similarity to a region within ETAA1-AAD, and targeted point mutations of aromatic amino acids in this sequence (AAD mut ) were sufficient to abrogate γH2AX formation triggered by overexpression of full-length ETAA1 or its AAD alone (Fig. 3a-c and Supplementary Fig. 3a) . Interestingly, ETAA1-AAD contains several (f) As in e, except that cells were treated with the indicated kinase inhibitors 10 min before addition of 4-OHT for 1 h (mean ± s.d.; n = 3 independent experiments; >3,000 cells analysed per condition). (g) U2OS cells transfected with empty vector (EV) or GFP-ETAA1 expression construct were subjected to GFP immunoprecipitation (IP) followed by immunoblotting for the indicated proteins. (h) In vitro kinase assay using purified ATR-ATRIP complex, recombinant ETAA1-AAD and MCM2(79-138) fragments (the latter serving as ATR model substrate) and radioactive ATP ( 32 P). Reactions were resolved on SDS-PAGE, stained with Colloidal Blue (CB), and 32 P incorporation was assessed by autoradiography. (i) Phospho-proteomic analysis of SILAC-labelled U2OS/GFP-ETAA1-AAD-ERT2 cells with and without 4-0HT treatment for 2 h to monitor phosphorylation changes triggered by forced nuclear expression of ETAA1-AAD. To identify ATR-dependent changes, ATR inhibitor (ATRi) or vehicle was added 15 min before 4-OHT treatment in an independent SILAC experiment (see Supplementary Fig. 3h for experimental set-up). The scatterplot shows the log 2 of mean SILAC ratios from four independent replicates of each experiment plotted against each other (see Supplementary Table 4 for full data). (j) Immunoblot analysis of U2OS/GFP-ETAA1-AAD-ERT2 cells treated with 4-OHT for the indicated times in the absence or presence of ATR inhibitor (ATRi). All scale bars, 10 µm. Data are representative of three (a,d,e,h) and two (g,j) independent experiments with similar results. Unprocessed original scans of blots (g-j) are shown in Supplementary Fig. 8 .
potential ATR phosphorylation sites and was phosphorylated by ATR in vitro (Fig. 3h and Supplementary Fig. 3a) . Moreover, endogenous ETAA1 showed a prominent ATR-dependent mobility shift after replication stress ( Supplementary Fig. 3g ), suggesting that it undergoes phosphorylation by ATR in response to such insults. Finally, mass spectrometry-based analysis of ATR-dependent phosphorylation changes induced by ETAA1-AAD overexpression showed that many ATR phosphorylation sites, including two in ETAA1-AAD itself, were upregulated under these conditions ( Fig. 3i and Supplementary  Fig. 3h ,i and Supplementary Table 4 ). We confirmed biochemically for H2AX and Chk1 that nuclear overexpression of ETAA1-AAD enhanced their ATR-dependent phosphorylation (Fig. 3j) . Altogether, these results demonstrate that ETAA1 harbours an AAD capable of directly and potently stimulating ATR kinase activity.
ETAA1 promotes ATR-mediated signalling and cell survival after replication stress Prompted by the findings above, we generated human HCT116 cell lines with targeted ETAA1 knockout (ETAA1∆) to investigate whether ETAA1 promotes ATR signalling following genotoxic stress. Indeed, while ablation of ETAA1 expression did not markedly affect overall cell cycle distribution ( Supplementary Fig. 4a ), ATR-dependent phosphorylation of RPA2 at Ser33 in response to CPT treatment was diminished in HCT116 ETAA1∆ cells ( Fig. 4a-c) . Likewise, RPA2-Ser4/Ser8 phosphorylation, which occurs downstream of Ser33 phosphorylation in CPT-treated cells 41 , was defective in ETAA1∆ cells (Fig. 4a,b ). Similar effects could be seen in HeLa cells ablated for ETAA1 expression ( Supplementary Fig. 4b ,c). Importantly, ETAA1 knockout did not impair RPA loading at CPT-induced DSBs ( Fig. 4b-e) , suggesting that ETAA1 loss impairs the response to CPT at the level of checkpoint signalling but not ssDNA generation via DSB end resection. In response to HU-induced helicase-polymerase uncoupling, ATR is essential to prevent RPA exhaustion and fork breakage by suppressing new origin firing, and inhibition of ATR in HU-treated cells therefore leads to excessive DSB formation and RPA hyperphosphorylation 42 . Consistently, HU-treated ETAA1∆ cells showed increased levels of RPA2 phosphorylation similar to the effect of ATR inhibition (Supplementary Fig. 4d ) 42 . In contrast, ATR-dependent phosphorylation of Chk1 after treatment with CPT or HU was not markedly altered in ETAA1-deficient cells ( Fig. 4a and Supplementary Fig. 4c ), indicating that loss of ETAA1 differentially affects ATR substrates.
Further supporting a role of ETAA1 in promoting ATR signalling, loss of ETAA1 rendered cells highly sensitive to replication stress induced by HU, CPT or mitomycin C (MMC), but not to clastogens such as etoposide that generate DSBs independently of replication ( Fig. 4f-h and Supplementary Fig. 4e-g ). Depletion of ETAA1 by siRNAs phenocopied the effect of ETAA1 knockout in cell survival assays ( Supplementary Fig. 4h-j) . Importantly, complementation of ETAA1∆ cells with ectopic ETAA1 wild type (WT), but not the RBM1+2, AAD and AAD mut mutants, fully rescued their hypersensitivity to CPT and partially restored survival after HU or MMC (Fig. 4f-h and Supplementary Fig. 4k ,l). As ETAA1 is a potent ATR activator, it is possible that expression of stably reconstituted GFP-ETAA1 at levels above that of endogenous ETAA1 ( Supplementary Fig. 4k ) may adversely affect cellular responses to certain genotoxic agents. We conclude that ETAA1 has an important role in promoting cell survival following replication stress, in a manner that requires both its ATR-activating and RPA-binding abilities.
ETAA1 is required for DNA replication integrity
We performed DNA fibre assays to understand how the absence of ETAA1 sensitizes cells to replication stress. By labelling cells with consecutive pulses of chlorodeoxyuridine (CldU) and iododeoxyuridine (IdU), we found that ETAA1 deficiency in both HCT116 and HeLa cells strongly reduced replication fork speed in otherwise unperturbed cells ( Fig. 5a and Supplementary Fig. 5a ). Moreover, ETAA1-deficient cells showed marked asymmetry of bidirectional replication forks from individual replication origins ( Fig. 5b and Supplementary  Fig. 5b ), suggesting that ETAA1 loss gives rise to a higher incidence of fork pausing and stalling. The diminished fork speed in ETAA1∆ cells was unexpected, given the similar cell cycle and EdU incorporation profiles of WT and ETAA1∆ cells ( Supplementary Fig. 4a,b) . However, in both HCT116 and HeLa cells, the slower fork progression in ETAA1∆ cells was accompanied by a dramatically increased rate of new origin firing ( Fig. 5c and Supplementary Fig. 5c ). Hence, loss of ETAA1 deregulates DNA replication initiation and elongation, similar to reported effects of ATR inhibition 43 . These defects were corrected by stably reconstituted WT ETAA1 (Fig. 5a-c ). Further supporting a key role of ETAA1 in promoting ATR signalling during replication, the basal γH2AX level in unstressed cells, which was ATR-dependent and restricted to S/G2 phase cells, was also prominently reduced in ETAA1-depleted cells, whereas depletion of TopBP1 had no effect ( Fig. 5d and Supplementary Fig. 5d-g ).
We next assessed how ETAA1 loss affects DNA replication status after fork-stalling insults. When cells were pulse-labelled with CldU and then with IdU in the presence of CPT, ETAA1 was again important for suppressing fork progression defects and new origin firing, in an AAD-dependent manner (Fig. 5e,f) . Furthermore, ETAA1∆ cells subjected to prolonged low-dose treatment with the DNA polymerase inhibitor aphidicolin showed elevated levels of abnormal nuclei, micronuclei and 53BP1 nuclear bodies in G1 phase 44 ( Fig. 5g,h ), further demonstrating a compromised ability of these cells to respond to replication problems. Thus, like ATR, ETAA1 is important for the integrity of DNA replication during both unperturbed and stressful conditions. ETAA1 and TopBP1 function in independent but parallel ATR activation pathways
As both ETAA1 and TopBP1 contain AADs, they might cooperatively promote ATR-dependent signalling after replication stress, and we therefore asked whether they function in joint or separate ATR activation pathways. Knockdown of TopBP1 or the 9-1-1 subunit RAD9 had no effect on the ability of ETAA1-AAD to stimulate ATR kinase activity ( Supplementary Fig. 6a-c) . Likewise, ETAA1 did not impair the ability of TopBP1-AAD to enhance ATR activity ( Supplementary  Fig. 6d ), suggesting that ETAA1 and TopBP1 function in independent ATR activation pathways. Remarkably, however, whereas individual depletion of TopBP1 or ETAA1 from HCT116 cells had only a modest impact on cellular fitness, simultaneous loss of these proteins profoundly impaired cell proliferation ( Fig. 6a ) and led to strongly increased rates of spontaneous DNA breakage in otherwise undamaged cells, as evidenced by neutral comet assays and markers of ATM kinase activity ( Fig. 6b-e ). This phenotype mimicked the effect of persistent ATR inhibition and could be seen in both HCT116 and HeLa ETAA1∆ cells, as well as after siRNA-mediated co-depletion of ETAA1 and TopBP1 ( 
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γH2AX Pos. by γH2AX formation (Fig. 6c) , suggesting that simultaneous loss of ETAA1 and TopBP1 leads to massive replication fork collapse 42 . A substantial proportion of these cells displayed fragmented nuclei with sub-G1 DNA content (Fig. 6c,d and Supplementary Fig. 6h ), a phenotype also observed after loss of ATR kinase activity 15, 45 . Cells lacking both ETAA1 and TopBP1 progressed abnormally through mitosis and frequently stained positive for γH2AX and the mitotic marker H3 pSer10 ( Supplementary Fig. 6i and Supplementary Videos 1 and 2), suggesting that they have a defective G2/M checkpoint and enter mitosis prematurely in the presence of DNA damage. In contrast, apoptosis inhibitors did not suppress nuclear fragmentation following combined ETAA1 and TopBP1 loss ( Supplementary Fig. 6j ), suggesting that this Fork progression (percentage of fibres) Supplementary Table 5 .
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or TopBP1 alone did not markedly impact ATR-dependent Chk1 phosphorylation in HCT116 and HeLa cells, simultaneous loss of these proteins strongly reduced Chk1 phosphorylation levels (Fig. 6b,g A R T I C L E S cells were more sensitive to low concentrations of ATR inhibitors than WT cells (Fig. 6h) , suggesting that loss of ETAA1 decreases the overall cellular capacity to activate ATR. Collectively, these findings suggest that ETAA1 functions in parallel with, but independent of, the canonical TopBP1 pathway in stimulating ATR kinase activity, and that both pathways make important contributions to ATR-mediated responses to replication stress.
ETAA1 and TopBP1 jointly promote ATR signalling in cancer cell lines
To further test the emerging model of ATR activation involving parallel TopBP1-and ETAA1-dependent pathways, we analysed ETAA1 expression status in a panel of human cancer cell lines. While the abundance of ETAA1 showed considerable variation across cell lines, we noted that U2OS osteosarcoma cells express abnormally low levels of ETAA1, which did not reflect reduced abundance of ETAA1 messenger RNA compared to other cell lines (Fig. 7a and Supplementary Fig. 7a,b) . Using the protein synthesis inhibitor cycloheximide, we found that unlike in HeLa cells, the half-life of ETAA1 was very short in U2OS cells (Supplementary Fig. 7c ), possibly accounting for their low ETAA1 expression levels. This provided a framework to further test the biological relevance of ETAA1 for ATR activation. Strikingly, knockdown of TopBP1 quantitatively suppressed HU-induced Chk1 phosphorylation in U2OS cells but not in HeLa cells that express higher levels of ETAA1 (Fig. 7b) . In contrast, depleting TopBP1 from U2OS cells stably expressing GFP-ETAA1 had little effect on Chk1 phosphorylation after HU treatment (Fig. 7b) . Similarly, loss of TopBP1 in U2OS but not HeLa cells markedly impaired ATR-dependent H2AX phosphorylation after HUinduced fork stalling, almost mimicking complete ATR inhibition, and this defect could be at least partially reversed by stable re-introduction of GFP-ETAA1 (Fig. 7b-d) . Consistently, combined knockdown of TopBP1 and ETAA1 was necessary to suppress ATR-dependent H2AX phosphorylation after HU treatment in HeLa cells ( Supplementary  Fig. 7d-f ). These findings provide further evidence that ETAA1 and TopBP1 function in independent but converging branches of ATR activation after replication stress (Fig. 7e) .
DISCUSSION
Activation of ATR in vertebrate cells is thought to rely largely on a pathway mediated by TopBP1, the only factor in higher eukaryotes known to harbour an AAD. Here, we have shown that ATR activation is not exclusively mediated by this pathway, but that human cells possess a second ATR-stimulatory mechanism that centres on ETAA1 (Fig. 7e) , a previously uncharacterized protein that undergoes enrichment at DNA damage sites via dual RPA1-and RPA2-binding motifs and contains a bona fide AAD. Similar findings were reported in ref. 46 . The ETAA1-AAD is a potent inducer of ATR kinase activation and is essential for the ability of ETAA1 to promote ATR signalling, replication integrity, and cell survival. While the known AADs share little sequence homology, Mec1/ATR activation by these domains involves pairs of aromatic amino acids whose spacing varies substantially among individual AADs 30, 47 . Interestingly, the sequence spanning a conserved aromatic residue within the TopBP1-AAD that is essential for its ability to promote ATR activation 26 shows homology to a region within ETAA1-AAD, point mutations of which prevent ATR activation by full-length ETAA1. Thus, the TopBP1 and ETAA1-AADs probably stimulate ATR kinase activity by analogous mechanisms.
The combination of RPA-binding and AAD motifs within ETAA1 may render it a potent ATR activator by obviating the need for ancillary factors targeting it to ATR-ATRIP complexes at genotoxic stress sites. Indeed, ETAA1 promotes ATR activation independently of the canonical TopBP1/9-1-1 axis; however, it remains to be seen whether ETAA1 collaborates with other factors in this process. Studies in mice have shown that the integrity of the TopBP1-AAD is essential for viability 28 . Our data suggest that the ETAA1 and TopBP1 pathways jointly promote ATR signalling, and that both pathways must be inactivated to robustly suppress ATR kinase activity in cells, illustrated by the synthetic lethality caused by combined ETAA1 and TopBP1 loss. An important question arising from these findings concerns the distribution of labour between TopBP1 and ETAA1 in activating ATR after different genotoxic stimuli. Conceivably, they could act on distinct pools of RPA-ssDNA-bound ATR-ATRIP complexes at DNA damage sites. ETAA1 might be particularly important for stimulating ATR kinase activity when long stretches of RPA-coated ssDNA are produced, such as during DSB end resection, where most ATR-ATRIP would be out of reach of 9-1-1-bound TopBP1 at ssDNA-dsDNA junctions. A similar role in promoting ATR kinase activity away from ssDNA-dsDNA junctions was recently suggested for the MRN component Nbs1, albeit in a manner that required TopBP1 41 . Recent work has shown that two distinct modes of Mec1/ATR signalling exist in yeast, one of which is highly active during normal replication but uncoupled from the canonical replication stress-induced checkpoint signalling pathway involving Mec1/Rad53 48 . It is tempting to speculate that the existence of two AAD-containing proteins in vertebrates may similarly enable different modes of ATR signalling in accordance with the status and integrity of DNA replication.
In preclinical studies, ATR kinase inhibitors have shown promising potential in cancer therapy, exacerbating oncogene-induced replication stress to sensitize cancer cells but not normal cells to DNA damage 49 . The functional status of ETAA1 in cancer cells, which typically experience high loads of replication stress 50 , may be an important determinant of their relative sensitivity to ATR inhibitors, since loss of ETAA1 leads to markedly reduced survival rates after treatment with these agents, particularly at low doses. This may be of clinical relevance, as the levels of ETAA1 expression vary considerably among different cancer cell lines and has important bearings on how ATRdependent signalling responses are instigated in different genetic backgrounds. Of note, variations in the ETAA1 locus are associated with increased pancreatic cancer risk 51, 52 . By promoting ATR-dependent responses to replication stress, ETAA1 may be an important factor in the cellular defence against cancer and other diseases associated with genomic instability.
Note added in proof: During the final stages of preparing the manuscript for publication, a study was published that describes an interaction of ETAA1 with RPA in the context of stalled replication forks (Feng, S. et al. J. Biol. Chem. http://dx.doi.org/10.1074/jbc.C116.747758; 2016).
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper
Statistical analysis of CHROMASS experiments.
Raw files were processed with MaxQuant Version 1.5.3.15. Label-free quantification (LFQ) intensities 53 were analysed by a permutation-based t-test using an FDR<0.02 and S0 = 1 (ref. 54) implemented in the statistical software package Perseus (http://www.biochem.mpg.de/5111810/perseus). ProteinGroups were filtered for proteins that were identified by at least two peptides and having at least two valid values in one of the conditions. Missing values were imputed into controls only and a one-sided test was used to determine the recruitment of proteins to DSB-containing chromatin. A top-level permutation-based q-value calculation was performed as described previously 31 . All results are reported in Supplementary  Table 1 . For recruitment kinetics, LFQ intensities on DSB-containing chromatin were normalized by the undamaged control, z-scored and visualized using R (https://www.r-project.org). Profiles for all proteins are reported in Supplementary  Table 2 . Protein recruitment triggered by inhibition of replicative polymerases by aphidicolin was determined by reanalysing a previously published data set 1 as above. Results are reported in Supplementary Table 3 .
Plasmids and siRNA. Full-length ETAA1 cDNA was cloned into pEGFP-C1 (Clontech) and pCR8/GW/TOPO (Invitrogen) using TOPO TA Cloning kit (Invitrogen). Point mutations and deletions in ETAA1 (RQ(902-3)AA, R902G, RBM11 (deletion of amino acids 603-618 ( 603-618)), RBM2( 892-926 ), RBM1+2( 603-618 and 892-926), AAD ( 56-220) and AAD mut (FW(106-7)AA)) were introduced with the QuikChange Site Directed Mutagenesis Kit (Stratagene), according to the manufacturer's protocol. Using Gateway LR Clonase (Invitrogen) ETAA1 WT, RPA1+2 and AAD were gateway cloned into the destination vector pcDNA4/TO/GFP for doxycyclineinducible expression. Expression constructs encoding GFP-tagged ETAA1 fragments were generated by inserting PCR products from pEGFP-C1-ETAA1 into pAcGFP-Nuc (GFP+3xNLS), to enforce nuclear expression. ETAA1-AAD (56-220) was further cloned into pAcGFP-ERT2 and a pGEX vector for bacterial expression. Bacterial expression construct encoding GST-tagged MCM2(79-138) was a gift from D. Cortez (Vanderbilt University, Tennessee, USA). Plasmids encoding GFP-tagged TopBP1-AAD (WT and W1145R mutant) were gifts from A. Kumagai (Caltech, California, USA). Plasmids for generation of HCT116 ∆ETAA1 cells using CRISPR/Cas9 were generated as described previously 55 using the pX459 plasmid (Addgene no. 62988) for Cas9 and gRNA delivery. Briefly, gRNA sequences were ordered as complementary primers, mixed in a 1:1 ratio and annealed. Subsequently, pX459 was digested using BbsI and the gRNA was introduced using a normal ligation reaction according to the manufacturer's instructions (New England Biolabs). The following sequences were used: ETAA1 sgRNA no. 1 forward primer: 5 -CACCGAAAACGCCGCACAAAACAG-3 ; ETAA1 sgRNA no. 1 reverse primer: 5 -AAACCTGTTTTGTGCGGCGTTTTC-3 ; ETAA1 sgRNA no. 3 forward primer: 5 -CACCGTTAAGCCAAGAACTGCCAG-3 ; ETAA1 sgRNA no. 3 reverse primer: 5 -AAACCTGGCAGTTCTTGGCTTAAC-3 .
For plasmid DNA transfections, FuGENE HD Transfection Reagent (Promega) or GeneJuice (Merck Millipore) was used according to the manufacturers' instructions. For siRNA transfections (typically 48-72 h), Lipofectamine RNAiMAX (Invitrogen) was used according to the manufacturer's protocol. All siRNAs were used at a final concentration of 50 nM. The following siRNA oligonucleotides were used: non-targeting control (CTRL): 5 -GGGAUACCUAGACGUUCUA-3 ; ATR: 5 -CCUCCGUGAUGUUGCUUGA-3 ; CtIP: 5 -GCUAAAACAGGAACGAAU C-3 ; ETAA1(no. 3): 5 -UGACAAAGCAGUUAGGUAA-3 ; ETAA1(no. 4): 5 -GAGCAAAACAAGAGGAAUU-3 ; RPA1: 5 -GGAAUUAUGUCGUAAGUCA -3 ; RAD51: 5 -GUAGAGAAGUGGAGCGUAA-3 ; Rad9A: 5 -GUCUUUCCU GUCUGUCUUC-3 ; BRCA2: siGENOME SMARTpool (cat. no.: M-003462-00), Dharmacon); ATM: siGENOME SMARTpool, (cat. no.: M-003201, Dharmacon); TopBP1: Silencer select s21823 (Life Technologies).
Cell culture and drug treatment. Human U2OS, HCT116 and HeLa cells were obtained from ATCC. All cell lines used in this study were cultured in DMEM containing 10% FBS, and were regularly tested for mycoplasma infection. No cell lines used in this study were found in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. The cell lines were not authenticated. To generate U2OS cell lines stably expressing GFP-ETAA1 WT, 1-870 or RQ(902-903)AA, U2OS cells were co-transfected with GFP-ETAA1 expression constructs together with pBabe-Puro and selected with puromycin, as described previously 56 . To generate HCT116 and HeLa ETAA1∆ cell lines, parental cells were transfected with pX459-sgETAA1 no. 1 and no. 3 (guide RNAs targeting unique loci in ETAA1) and selected briefly with puromycin during clonal selection. Clones were screened for ETAA1 expression by immunoblotting. All ETAA1 cell lines were subsequently screened for expression of Cas9 by immunoblotting to ensure no stable integration of the Cas9 nuclease. The ETAA1∆-1 and ETAA1∆-3 cell lines were derived independently with ETAA1 gRNA no. 1 and no. 3, respectively. To generate stable cell lines inducibly expressing GFP-ETAA1 constructs in a U2OS or HCT116 ETAA1∆ background, cells were co-transfected with pcDNA4/TO/GFP-ETAA1 constructs and pcDNA6/TR (Invitrogen) and positive clones were selected by incubation in medium containing blasticidin S (Invitrogen) and zeocin (Invitrogen) for 14 days. Unless otherwise indicated, the following drug concentrations were used: camptothecin (1 µM, Sigma Aldrich), hydroxyurea (2 mM, Sigma Aldrich), mitomycin C (30 ng ml −1 , Sigma Aldrich), ATR inhibitors (AZ20, 1µM, Sigma Aldrich; ETP-46464, 2 µM), ATM inhibitor (10 µM, KU-60019, Selleck Chem), DNA-PK inhibitor (2 µM, NU7441, Selleck Chem), 4-hydroxytamoxifen (4-OHT, 1 µM, Sigma Aldrich), cycloheximide (100 µg µl −1 , Sigma Aldrich) and doxycycline (1 µg ml −1 , Sigma Aldrich).
Immunochemical methods.
Immunoblotting and immunoprecipitation were performed as described previously 57 . Briefly, cells were lysed in EBC buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 1 mM EDTA; 0.5% NP40; 1 mM dithiothreitol) containing protease and phosphatase inhibitors. All immunoprecipitations were sonicated or benzonase-treated to minimize chromatin-mediated interactions. For chromatin fractionation, cells were lysed in Buffer 1 (100 mM NaCl; 300 mM sucrose; 3 mM MgCl 2 ; 10 mM PIPES, pH 6.8; 1 mM EGTA; 0.2% Triton X-100) containing protease, phosphatase and DUB inhibitors and incubated on ice for 5 min. After centrifugation, the pellet was washed in Buffer 1 and resuspended in Buffer 2 (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 5 mM EDTA; 1% Triton X-100; 0.1% SDS) containing protease, phosphatase and DUB inhibitors. Lysates were then incubated for 10 min on ice and sonicated. All immunoblotting experiments were performed at least twice, and representative data are shown.
Antibodies used in this study included: ATR (sc-1887, Santa Cruz (1:500 dilution for immunoblotting)), ATRIP (no. 2737, Cell Signaling (1:1,000)), ATM (ab31842 (Clone 11G12), Abcam (1:1,000)), RPA1 (Ab79398, Abcam (1:1,000) and sc-14696, Santa Cruz (1:500)), GFP (11814460001, Roche (1:1,000) and sc-9996 (Clone B2), Santa Cruz (1:1,000)), TopBP1 (A300-111A, Bethyl (1:1,000)), CtIP (A300-488A, Bethyl (1:1,000)), BRCA2 (OP95 (Clone Ab-1), Millipore (1:500)), RAD51 (PC130, Ab-1, Millipore (1:500)), XPA (A301-780A, Bethyl (1:500)), SMARCAL1 (A301-616A, Bethyl (1:1,000)), actin (MAB1501 (Clone C4), Millipore (1:20,000)), RPA2 pSer33 (A300-246A, Bethyl (1:1,000)), Chk2 pThr68 (2661, Cell Signaling (1:500)), Rad9A (sc-8324, Santa Cruz (1:500)), Chk1 pSer317 (2344, Cell Signaling (1:1,000)), Chk1 (sc-8408 (Clone G4), Santa Cruz (1:1,000)), Chk1 pSer345 (2348, Cell Signaling (1:1,000)), γH2AX (2577, Cell Signaling (1:1,000), and 05-636 (Clone JBW301), Millipore (1:1,000)), H3 pSer10 (06-570, Millipore (1:1,000)), FLAGtag (F1804 (Clone M2), Sigma Aldrich (1:500)), MCM6 (C-20, sc-9843, Santa Cruz (1:1,000)), RPA2 (NA19L (Clone Ab-3), RPA34-20, Calbiochem (1:1,000), and ab76420, Abcam (1:1,000)), RPA2-pSer4/Ser8 (A300-245A, Bethyl (1:1,000)), RPA2 pT21 (ab109394, Abcam (1:2,000)), 53BP1 (H-300, sc22760, Santa Cruz (1:500)). Polyclonal ETAA1 antibody was produced in sheep, using a purified fragment spanning the N-terminal half of human ETAA1 expressed in bacteria as an immunogen.
Cell survival and comet assays. For colony formation assays, cells were seeded in triplicate (6 cm dishes) per condition and allowed to adhere for a minimum of 16 h. Cells were then treated with the indicated concentrations of HU, CPT and MMC for 24 h or with the indicated concentration of etoposide for 1 h, washed extensively and released into fresh medium. After 10-12 days plates were washed once in PBS, left to dry and stained with cell staining solution (0.5% w/v Crystal Violet, 25% v/v methanol). Finally, the plates were washed three times in deionized water. The colonies were counted manually and the surviving fraction was calculated as: colonies/(seeded colonies × plating efficiency). To measure lethality of TopBP1 depletion in HCT116 and ETAA1∆ cell lines, plating efficiencies of siTopBP1-transfected cells were normalized those of cells transfected with control siRNA for each cell line, and then normalized to HCT116 WT. The SRB cell proliferation assay was performed as described previously 58 . Briefly, HCT116 WT or ETAA1∆ cells were seeded in 96-well plates (750-1,500 cells per well). Twenty-four hours later, cells were treated with the indicated concentrations of ATR inhibitor (AZ20, Sigma Aldrich). Once the untreated cells reached near-confluency, cells were fixed in 10% (w/vol) trichloroacetic acid for 30 min at 4 • C, washed four times with deionized water and stained with sulforhodamine B (SRB) (0.4% SRB in 1% acetic acid) for 15 min at room temperature. Subsequently the wells were washed four times with 1% acetic acid and air-dried for at least 1 h. The dried SRB precipitate was then dissolved in 10 mM Tris buffer (pH 8.0) and colorimetric changes were measured DOI: 10.1038/ncb3422
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on a FLUOstar omega 96-well plate reader. The experiment was repeated three times, and each individual experiment consisted of three technical replicates. Neutral comet assays (Trevigen) to monitor DSB formation were performed according to the manufacturer's instructions.
In vitro ATR kinase assay. GST-tagged fragments of ETAA1 (amino acids 56-220 ) and MCM2 (amino acids 79-138) were expressed in Rosetta 2 (DE3) pLysS bacteria and purified using glutathione-based affinity purification. Purified FLAG-ATR/cMyc-ATRIP mixture (100 ng) (no. 14-953, Eurofins) was added to recombinant GST-ETAA1(56-220) (500 ng) and incubated for 20 min on ice. The kinase reactions were started by adding 1×kinase buffer (10 mM MnCl 2 ; 1 mM dithiothreitol, 50 mM beta-glycerophosphate; 100 µM ATP; [γ-32 P]ATP (10 µCi, Perkin Elmer) and GST-MCM2 (3,5 µg), which served as ATR substrate. Reactions were incubated for 20 min at 30 • C with gentle shaking and terminated by adding Laemmli buffer and boiling the samples at 95 • C for 10 min. Samples were then resolved on SDS-PAGE, stained with Colloidal Blue (Life Technologies) and vacuum-dried. Relative phosphorylation was assayed by autoradiography.
Immunofluorescence, laser microirradiation, microscopy and high-content imaging. Cells were pre-extracted in PBS containing 0.2% Triton X-100 for 2 min on ice, before fixation with 4% formaldehyde for 15 min. If cells were not preextracted, they were subjected to a permeabilization step with PBS containing 0.2% Triton X-100 for 5 min and incubated with primary antibodies diluted in DMEM supplemented with 10% FBS for 1 h at room temperature. Following staining with secondary antibodies (Alexa Fluor; Life Technologies) diluted in DMEM+FBS for 1 h at room temperature, coverslips were mounted in Vectashield mounting medium (Vector Laboratories) containing the nuclear stain DAPI. For EdU staining, cells were treated with EdU (10 µM) for 30 min before fixation, and then stained using the Click-iT Plus EdU Alexa Fluor 647 Imaging Kit (Invitrogen) according to the manufacturer's instructions. Confocal microscopy and laser microirradiation was performed essentially as described previously 56 . Briefly, confocal images were acquired with an LSM780 confocal microscope (Carl Zeiss Microimaging) mounted on a Zeiss-Axiovert 100M equipped with a Plan-Apochromat 40×/1.3 oil immersion objective, using standard settings. Image acquisition and analysis was carried out with ZEN2010 software. Raw images were exported as TIFF files and if adjustments in image contrast and brightness were applied, identical settings were used on all images of a given experiment. All immunofluorescence experiments were performed at least twice, and representative data are shown. Quantitative image-based cytometry (QIBC) was performed as described previously 42 . Briefly, cells were pre-extracted or not, fixed and stained as described above. Nuclear DNA was counterstained with DAPI (Molecular Probes) alongside incubation with secondary antibodies. Cells were mounted onto glass slides using ProLong Gold Antifade (Invitrogen, Molecular Probes). Images were acquired with an Olympus IX-81 wide-field microscope equipped with an MT20 Illumination system and a digital monochrome Hamamatsu C9100 CCD (charge-coupled device) camera. Olympus UPLSAPO 10×/0.4 NA, 20×/0.75 NA objectives were used. Automated and unbiased image analysis was carried out with the ScanR analysis software. Unless otherwise stated, between 1,000-5,000 cells were analysed per condition. Data were exported and processed using Spotfire (Tibco) software.
DNA fibre assays. Exponentially growing cells (1 × 10
6 ) were incubated with CldU (25 µM) for 20 min followed by IdU (250 µM) for 20 min. Cells were then trypsinized and resuspended in PBS. Cell suspension (2 µl) was spotted onto Superfrost glass slides and lysed in buffer containing 200 mM Tris-HCl, pH 5.5; 50 mM EDTA; 0.5% SDS for 2 min. Slides were tilted at an angle to allow the DNA to run slowly down the slide. Slides were air-dried before fixing in 3:1 methanol/acetic acid. DNA fibre spreads were denatured with 2.5 M HCl for 80 min before blocking in 2% BSA-PBS with 0.1% Tween for 15 min. Slides were then incubated with rat anti-BrdU (Abcam, ab6326) for 1 h at 1:100 to detect CldU. Slides were washed in PBS-Tween and PBS before antibody crosslinking in 4% formaldehyde for 10 min. Slides were then incubated with Alexa Fluor 594 goat anti-rat antibody (ThermoFisher) for 1 h at 1:100. Following similar washes, slides were incubated with mouse anti-BrdU (BD Bioscience, no. 347580) at 1:500 overnight at 4 • C to detect IdU. Slides were washed and incubated with Alexa Fluor 488 goat anti-mouse antibody (ThermoFisher) for 1 h at 1:100. After washing, the slides were air-dried and mounted with 50 µl of Vectashield mounting medium (Vector Laboratories). Track lengths were measured using ImageJ software. For CPT treatment, cells were incubated with CldU as stated above, followed by IdU (250 µM) and CPT (1 µM) for 40 min before trypsinization and slide preparation as above.
Phosphoproteomics. U2OS cells stably expressing GFP-ETAA1-AAD-ERT2 were SILAC labelled by culturing in DMEM SILAC medium (ThermoFisher, A14431-01) supplemented with Lys0,Arg0 (Light (L)) or Lys8,Arg10 (Heavy (H)) 59 . To induce nuclear localization of GFP-ETAA1-AAD-ERT2, cells were incubated with 4-OHT for 2 h. Where indicated, ATR inhibitor (2 µM) was added 15 min before 4-OHT treatment. All cells were lysed directly on the cell culture plates using 6 M guanidinium-HCl lysis buffer (pH 8.5), boiled and sonicated. Cell lysates (1.5 mg of each) were combined, and phosphopeptides were prepared and analysed by mass spectrometry as described previously 60 . Quantification of phosphopeptides is reported in Supplementary Table 4 .
Quantification of mRNA levels by quantitative PCR. RNA was purified from cells using the RNeasy kit (Qiagen). cDNA was generated by PCR with reverse transcription (iScript cDNA Synthesis Kit, Bio-Rad) according to the manufacturer's protocol. Real-time quantitative PCR was performed using the Stratagene Mx3005P System and Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent). Ubiquitin or GAPDH mRNA levels were used as a control for normalization. For amplification of the indicated cDNAs, the following primers were used: ETAA1 no. 1 (forward): 5 -ATGAGTCGGCGAAGGAAACAT-3 ; ETAA1 no. 1 (reverse): 5 -TC GGGGTTACTTTTACTGCAC-3 ; GAPDH (forward): 5 -CAGAACATCATCCC TGCCTCTAC-3 ; GADPH (reverse): 5 -TTGAAGTCAGAGGAGACCACCTG-3 ; ubiquitin (forward): 5 -CACTTGGTCCTGCGCTTGA-3 ; ubiquitin (reverse): 5 -CAATTGGGAATGCAACAACTTTAT-3 .
Statistics and reproducibility.
For all experiments, samples were not randomized and the investigators were not blinded to the group allocation during experiments and outcome assessment. No samples were excluded from the analysis and no statistical method was used to predetermine sample size. All experiments in this study were repeated independently at least twice. Representative images are shown in Figs 1e,g, 2a-c,e, 3a,d ,e,g,h,j, 4a-d, 6b,d-g and 7a,b and in Supplementary  Figs 2a,b,d-f, 3f,g, 4c,d ,j,k, 5d, 6c,e-g,i and 7c,f. Information about statistical tests and how many times individual experiments were repeated with similar results is provided in the figure legends.
Data availability. All raw mass spectrometry proteomics data reported in this study have been deposited to the ProteomeXchange Consortium 61 (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository with the data set identifier PXD003529. Source data for Figs 5a-c,e,f,h, 6e and Supplementary Fig. 7a ,b are provided in Supplementary Table 5 . All other data supporting the findings of this study are available from the authors on request.
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Haahr et al. Figure S1 70  80  90  100  110  120  130  140  150  160  170  180  190  200  210  220 Figure 3 Characterization of an ATR-activating domain (AAD) in ETAA1. a. Location and sequence conservation of the ETAA1 AAD. Highly conserved residues are highlighted (blue). Residues mutated to alanine in order to generate the AAD mut allele are indicated in red. b. Overview of GFP-ETAA1 fragments used and their ability to induce pan-nuclear γ-H2AX formation when overexpressed in U2OS cells. c. U2OS cells stably expressing GFP-ETAA1-AAD-ERT2 were exposed to 4-OHT for various times and immunostained with γH2AX antibody. Mean γH2AX intensity per nucleus was determined by quantitative image analysis (n=3000 cells per condition). d. U2OS cells transfected with GFP empty vector (EV) or constructs encoding GFP-ETAA1-AAD or GFPTopBP1-AAD were fixed and stained with γH2AX antibody. Cells were gated according to mean GFP intensity per nucleus (shades of green). γH2AX signal per nucleus was determined by quantitative image analysis (1000 cells analyzed per condition) (bottom). e. Quantitative image analysis of U2OS/GFP-ETAA1-AAD-ERT2 cells treated with 4-OHT for 2 h and co-immunostained with antibodies to RPA1 and γH2AX (5000 cells analyzed per condition). The color of each dot represents mean γH2AX intensity per nucleus, ranging from low (grey) to high (red) (left). Bar chart shows the mean γH2AX and RPA1 signals per nucleus normalized to mock control (right). f. U2OS/GFP-ETAA1-AAD-ERT2 cells left untreated or induced to express the transgene by addition of Doxycycline (DOX) were subjected to GFP immunoprecipitation (IP) followed by immunoblotting with GFP and ATR antibodies. g. HCT116 cells were exposed to HU (3 h) or CPT (2 h) in the presence or absence of ATR inhibitor (ATRi) and analyzed by immunoblotting with indicated antibodies. Asterisk denotes an unspecific band recognized by the ETAA1 antibody. h. Setup of phospho-proteomics experiments in Figure 3i . Cells were subjected to SILAC labeling with light medium (L; Lys0,Arg0) or heavy medium (H; Lys8,Arg10) and treated with 4-OHT and/or ATR inhibitor (ATRi) for 1 h as indicated. i. Venn diagrams showing overlap between regulated phosphorylation sites (N denotes total number) in mass spectrometry experiments in (h). Data are representative of three (e,f,g) and two (c,d) independent experiments with similar results. Uncropped blots (f,g) are shown in Figure S8 . HeLa cells transfected with indicated siRNAs were labeled with EdU, fixed, and processed for γH2AX and EdU staining. Cells were then analyzed by quantitative image analysis (n=3000 cells per condition). Cells were gated into G1 and S/G2 cell populations based on EdU and DAPI intensities, and analyzed for mean γH2AX signal per nucleus. Box plot shows median, upper and lower quartiles, 95% values (whiskers) and outliers. f. As in (e), but using untransfected HeLa WT and ETAA1Δ cell lines (n=3000 cells per condition) Box plot shows median, upper and lower quartiles, 95% values (whiskers) and outliers. Data are representative of three (e) and two (d,f) independent experiments with similar results. Fiber data (a-c) represents a single technical repeat but represents a biological repeat of data in Figure  5a -c. Uncropped blots (d) are shown in Figure S8 . Supplementary Figure 7 Characterization of ETAA1 in HeLa and U2OS cells. a. qPCR analysis of ETAA1 mRNA levels in different cell lines relative to HCT116 cells. Primers to GAPDH were used as a control for normalization (mean±SEM;n=3 independent experiments). b. As in (a), but using primers to ubiquitin as a control for normalization (mean±SEM;n=3 independent experiments). c. U2OS and HeLa were treated with Cycloheximide (CHX) for the indicated times and analyzed by immunoblotting to assess the half-life of ETAA1. Cyclin F was as a positive control for the effect of CHX. Asterisk denotes an unspecific band recognized by the ETAA1 antibody. d. HeLa cells transfected with indicated siRNAs were treated with HU and/or ATR inhibitor (ATRi), stained with RPA1 and γH2AX antibodies and subjected to quantitative image analysis (3500 cells analyzed per condition). The contribution of ATR to the γH2AX signal, based on the ATRi-treated sample, is indicated in blue. Cells displaying maximal HU-induced RPA chromatin loading accompanied by ATM-dependent but ATR-independent H2AX hyperphosphorylation reflecting fork breakage 42 are indicated in pink. e. Quantification (mean±SEM) of γH2AX signal per nucleus of the ATR-gated population (blue) in (d) (n=1500 cells per condition). f. Immunoblot analysis of the experiment in (c). Data are representative of two (c-f) independent experiments with similar results. Source data (a,b) are provided in Table  S5 . Uncropped blots (c,f) are shown in Figure S8 . Haahr et al. Figure S8 Supplementary Figure 8 Haahr et al. Figure S8 Supplementary Figure 8 continued 
